Mongolia
Tuberculosis profile
Population  2013 2.8 million
Estimates of TB burden * 2013 Number (thousands) Rate
(per 100 000 population)
Mortality (excludes HIV+TB) 0.14 (0.05–0.27) 4.9 (1.8–9.5)
Mortality (HIV+TB only) <0.01 (<0.01–<0.01) 0.04 (0.01–0.08)
Prevalence  (includes HIV+TB) 7.2 (3.4–12) 254 (119–438)
Incidence  (includes HIV+TB) 5.1 (4.6–6) 181 (163–210)
Incidence (HIV+TB only) <0.01 (<0.01–0.014) 0.21 (0.2–0.51)
Case detection, all forms (%) 84 (72–94)    
Estimates of MDR-TB burden * 2013   New   Retreatment
% of TB cases with MDR-TB 1.4 (0.7–2.5) 34 (29–38)
MDR-TB cases among notified pulmonary
TB cases
33 (16–59) 210 (180–240)
TB case notifications 2013 New ** Relapse
Pulmonary, bacteriologically confirmed 1 622   220
Pulmonary, clinically diagnosed 733   0
Extrapulmonary 1 756   0
       
Total new and relapse 4 331    
Previously treated, excluding relapses 402    
Total cases notified 4 733    
Among 4 331 new and relapse cases:
359 (8%) cases aged under 15 years; male:female ratio: 1.3
Reported cases of RR-/MDR-TB 2013 New Retreatment Total **
Cases tested for RR-/MDR-TB 938 (58%) 3 158 (508%) 4 096
Laboratory-confirmed RR-/MDR-TB cases     267
Patients started on MDR-TB treatment     192
TB/HIV 2013 Number (%)
TB patients with known HIV status 3 659 (77)
HIV-positive TB patients 5 (<1)
HIV-positive TB patients on co-trimoxazole preventive therapy (CPT) 2 (40)
HIV-positive TB patients on antiretroviral therapy (ART) 1 (20)
HIV-positive people screened for TB 120  
HIV-positive people provided with IPT 0  
Treatment success rate (%)
New and relapse cases registered in 2012 88
Previously treated cases, excluding relapse, registered in 2012 77
HIV-positive TB cases, all types, registered in 2012 100
RR-/MDR-TB cases started on second-line treatment in 2011 67
XDR-TB cases started on second-line treatment in 2011  
Laboratories 2013  
Smear (per 100 000 population) 1.3
Culture (per 5 million population) 3.5
Drug susceptibility testing (per 5 million population) 1.8
Sites performing Xpert MTB/RIF 1
Is second-line drug susceptibility testing available? Yes, in country
Financing TB control 2014  
National TB programme budget (US$ millions) 6.7
% Funded domestically 63%
% Funded internationally 36%
% Unfunded 1%
* Ranges represent uncertainty intervals
** Includes cases with unknown previous TB treatment history
***
(Rate per 100 000 population per year)
Mortality graph
   Mortality  (excludes HIV+TB)

(Rate per 100 000 population)
Prevalence graph
   Prevalence

(Rate per 100 000 population per year)
Incidence graph
   Notified (new and relapse)   Incidence
   Incidence (HIV+TB only)

(Number of patients)
CPT ART graph
   HIV-positive TB patients
   on CPT   on ART

Treatment success rate (%)
tx success graph
   New   Retreatment
   New and relapse   Retreatment, excluding
relapse
   HIV-positive   RR-/MDR-TB   XDR-TB

Total budget (US$ millions)
Budget funding Graph
__Funded domestically__Funded internationally
__Unfunded
 
 Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries.
 Generated: 2015-04-25 Data: www.who.int/tb/data